GalindoRJ, AleppoG: Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology. Diabetes Res Clin Pract, 2020; 170:108502.
2.
WanW, SkandariMR, MincA, et al.: Cost-effectiveness of continuous glucose monitoring for adults with type 1 diabetes compared with self-monitoring of blood glucose: the DIAMOND randomized trial. Diabetes Care, 2018; 41:1227–1234.
3.
PolonskyWH, FortmannAL: Impact of real-time continuous glucose monitoring data sharing on quality of life and health outcomes in adults with type 1 diabetes. Diabetes Technol Ther, 2021; 23:195–202.
4.
HuangES, O'GradyM, BasuA, et al.: The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes care, 2010; 33:1269–1274.
5.
PeekME, ThomasCC: Broadening access to continuous glucose monitoring for patients with type 2 diabetes. JAMA, 2021; 325:2255–2257.
6.
BaruaS, SabharwalA, GlantzN, et al.: Dysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: insights from continuous glucose monitoring. EClinical Medicine, 2021; 35:100853.
7.
GraceT, SlyerJ: Use of real-time continuous glucose monitoring (rtCGM) improves glycemic control and other clinical outcomes in type 2 diabetes patients treated with less intensive therapy. Diabetes Technol Ther, 2022; 24:26–31.
8.
MartensT, BeckRW, BaileyR, et al.: Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA, 2021; 325:2262–2272.
9.
KarterAJ, ParkerMM, MoffetHH, et al.: Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA, 2021; 325:2273–2284.
10.
BeckRW, RiddlesworthTD, RuedyK, et al.: Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med, 2017; 167:365–374.
11.
YooHJ, AnHG, ParkSY, et al.: Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract, 2008; 82:73–79.
12.
VigerskyRA, FondaSJ, ChellappaM, et al.: Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care, 2012; 35:32–38.
13.
JacksonMA, AhmannA, ShahVN: Type 2 diabetes and the use of real-time continuous glucose monitoring. Diabetes Technol Ther, 2021; 23(S1):S27–S34.
14.
HaakT, HanaireH, AjjanR, et al.: Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther, 2017; 8:55–73.
15.
HaakT, HanaireH, AjjanR, et al.: Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther, 2017; 8:573–586.
16.
AjjanRA, JacksonN, ThomsonSA: Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: a pilot, multicentre, randomised controlled trial. Diab Vasc Dis Res, 2019; 16:385–395.
17.
KrakauerM, BoteroJF, Lavalle-GonzálezFJ, et al.: A review of flash glucose monitoring in type 2 diabetes. Diabetol Metab Syndr, 2021; 13:42.
18.
WrightEE, KerrMSD, ReyesIJ, et al.: Use of flash continuous glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr, 2021; 34:184–189.
19.
PetersAL, AhmannAJ, HirschIB, RaymondJK: Advances in glucose monitoring and automated insulin delivery: supplement to endocrine society clinical practice guidelines. J Endocr Soc, 2018; 2:1214–1225.
20.
GrunbergerG, SherrJ, AllendeM, et al.: American Association of Clinical Endocrinology Clinical Practice Guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021; 27:505–537.
21.
American Diabetes Association Professional PracticeCommittee, American Diabetes Association Professional PracticeCommittee, DrazninB, et al.6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care, 2022; 45(Suppl. 1):S83–S96.
22.
American Diabetes Association Professional PracticeCommittee, American Diabetes Association Professional PracticeCommittee, DrazninB, et al.: 7. Diabetes technology: standards of medical care in diabetes-2022. Diabetes Care, 2022; 45(Suppl. 1):S97–S112.
23.
PetersAL, AhmannAJ, BattelinoT, et al.: Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2016; 101:3922–3937.
24.
GrunbergerG, HandelsmanY, BloomgardenZT, et al.: American Association of Clinical Endocrinologists and American College of Endocrinology 2018 position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. Endocr Pract, 2018; 24:302–308.
25.
KompalaT, NeinsteinA: A new era: increasing continuous glucose monitoring use in type 2 diabetes. Am J Manag Care, 2019; 25(4 Spec No.):SP123–SP126.
26.
IdaS, KanekoR, MurataK: Utility of real-time and retrospective continuous glucose monitoring in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Diabetes Res, 2019; 2019:4684815.
27.
TsujiS, IshikawaT, MoriiY, et al.: Cost-effectiveness of a continuous glucose monitoring mobile app for patients with type 2 diabetes mellitus: analysis simulation. J Med Internet Res, 2020; 22:e16053.
28.
FondaSJ, GrahamC, MunakataJ, et al.: The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes. J Diabetes Sci Technol, 2016; 10:898–904.
29.
LinR, BrownF, JamesS, et al.: Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus. Diabet Med, 2021; 38:e14528.
30.
Garcia-LorenzoB, Rivero-SantanaA, Vallejo-TorresL, et al.: Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. J Eval Clin Pract, 2018; 24:772–781.
31.
OserTK, LitchmanML, AllenNA, et al.: Personal continuous glucose monitoring use among adults with type 2 diabetes: clinical efficacy and economic impacts. Curr Diab Rep, 2021; 21:49.
32.
AndersonJE, GavinJR, KrugerDF: Current eligibility requirements for CGM coverage are harmful, costly, and unjustified. Diabetes Technol Ther, 2020; 22:169–173.
33.
BartelmeA, BridgerP: The role of reimbursement in the adoption of continuous glucose monitors. J Diabetes Sci Technol, 2009; 3:992–995.
34.
DixonRF, ZisserH, LayneJE, et al.: A virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits. J Diabetes Sci Technol, 2020; 14:908–911.
35.
GalindoRJ, ParkinCG, AleppoG, et al.: What's wrong with this picture? A critical review of current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring. Diabetes Technol Ther, 2021; 23:652–660.
36.
Centers for Medicare and Medicaid Services: Medicare Coverage Database. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822 (accessed November14, 2021).
37.
JaklevicMC: Start-ups tout continuous glucose monitoring for people without diabetes. JAMA, 2021; 325:2140–2142.
38.
MillerEM: Using continuous glucose monitoring in clinical practice. Clin Diabetes, 2020; 38:429–438.
39.
EspinozaJ, XuNY, NguyenKT, KlonoffDC: The need for data standards and implementation policies to integrate CGM data into the electronic health record. J Diabetes Sci Technol, 2021:19322968211058148.
40.
WalkerAF, CuttrissN, HallerMJ, et al.: Democratizing type 1 diabetes specialty care in the primary care setting to reduce health disparities: project extension for community healthcare outcomes (ECHO) T1D. BMJ Open Diabetes Res Care, 2021; 9:e002262.
41.
VigerskyRA, FishL, HoganP, et al.: The clinical endocrinology workforce: current status and future projections of supply and demand. J Clin Endocrinol Metab, 2014; 99:3112–3121.
42.
GalRL, CohenNJ, KrugerD, et al.: Diabetes telehealth solutions: improving self-management through remote initiation of continuous glucose monitoring. J Endocr Soc, 2020; 4:bvaa076.
43.
Van DrilE, SchumacherC: Impact of professional continuous glucose monitoring by clinical pharmacists in an ambulatory care setting. JACCP, 2019; 2:638–644.
44.
SherrillCH, HouptCT, DixonEM, RichterSJ: Effect of pharmacist-driven professional continuous glucose monitoring in adults with uncontrolled diabetes. J Manag Care Spec Pharm, 2020; 26:600–609.
45.
SimonsonGD, BergenstalRM, JohnsonML, et al.: Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care. J Diabetes Sci Technol, 2021; 15:539–545.
46.
YinglingL, AllenNA, LitchmanML, et al.: An evaluation of digital health tools for diabetes self-management in Hispanic adults: exploratory study. JMIR Diabetes, 2019; 4:e12936.
47.
CavanaughK, WallstonKA, GebretsadikT, et al.: Addressing literacy and numeracy to improve diabetes care: two randomized controlled trials. Diabetes Care, 2009; 32:2149–2155.
48.
ZauggSD, DogbeyG, CollinsK, et al.: Diabetes numeracy and blood glucose control: association with type of diabetes and source of care. Clin Diabetes, 2014; 32:152–157.
49.
IsaacsD, BelliniNJ, BibaU, et al.: Health care disparities in use of continuous glucose monitoring. Diabetes Technol Ther, 2021; 23(S3):S81–S87.
50.
AgarwalS, SchechterC, GonzalezJ, LongJA: Racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther, 2021; 23:306–313.
51.
RuedyKJ, ParkinCG, RiddlesworthTD, et al.: Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol, 2017; 11:1138–1146.
52.
Hill-BriggsF, AdlerNE, BerkowitzSA, et al.: Social determinants of health and diabetes: a scientific review. Diabetes Care, 2020; 44:258–279.
53.
PazR, RouhanianM, VogtK: Glycemic control and sponsor rank of military dependents with type 1 diabetes mellitus. Pediatr Diabetes, 2016; 17:449–457.
54.
WherryK, ZhuC, VigerskyRA: Inequity in adoption of advanced diabetes technologies among Medicare fee-for-service beneficiaries. J Clin Endocrinol Metab, 2021:dgab869.
